Literature DB >> 24078150

Up-regulation of tripartite motif-containing 29 promotes cancer cell proliferation and predicts poor survival in colorectal cancer.

Tao Jiang1, Hua-mei Tang, Su Lu, Dong-wang Yan, Yin-xue Yang, Zhi-hai Peng.   

Abstract

Tripartite motif-containing 29 (TRIM29), also known as ataxia-telangiectasia group D, is structurally a member of the tripartite motif family of proteins, which characterized by the conserved RING finger, B-box, and coiled-coil domains. TRIM29 functions as an oncogene or a tumor suppressor depending on the tumor types. In this study, we aim to evaluate whether TRIM29 affects the tumorigenesis and progression of colorectal cancer. The expression of TRIM29 was investigated using real-time PCR in 40 pairs of colorectal cancer tissues and immunohistochemistry on a tissue microarray containing 203 cases of primary colorectal cancer paired with non-cancerous tissues. Down-regulation of TRIM29 was achieved by transient transfection in RKO cell lines, and the effects of TRIM29 on tumor proliferation were evaluated by MTT and plate colony formation assays. Results indicated that TRIM29 expression was much higher in colorectal cancer tissues and significantly associated with the depth of tumor invasion, lymph node metastasis, distant metastasis, histological differentiation, vascular invasion, ki-67 index, and advanced tumor stage. Patients with TRIM29-positive tumors had a higher recurrence rate and poorer survival than patients with TRIM29-negative tumors. In multivariate analyses, the TRIM29 expression was an independent factor for determining colorectal cancer prognosis after surgery. Moreover, down-regulation of TRIM29 inhibited tumor cell proliferation in vitro. In conclusion, TRIM29 plays an important role in promoting colorectal cancer progression. Our findings suggest that TRIM29 may serve as a novel biomarker for tumor recurrence and survival for colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24078150     DOI: 10.1007/s12032-013-0715-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

Review 1.  A novel zinc finger coiled-coil domain in a family of nuclear proteins.

Authors:  B A Reddy; L D Etkin; P S Freemont
Journal:  Trends Biochem Sci       Date:  1992-09       Impact factor: 13.807

2.  Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

Authors:  Lars Dyrskjøt; Mogens Kruhøffer; Thomas Thykjaer; Niels Marcussen; Jens L Jensen; Klaus Møller; Torben F Ørntoft
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

3.  Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung.

Authors:  Lesleyann Hawthorn; Leighton Stein; Jenniffer Panzarella; Gregory M Loewen; Heinz Baumann
Journal:  Lung Cancer       Date:  2006-06-06       Impact factor: 5.705

Review 4.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

5.  Reduced expression of PER3 is associated with incidence and development of colon cancer.

Authors:  Xiaoliang Wang; Dongwang Yan; Mujian Teng; Junwei Fan; Chongzhi Zhou; Dawei Li; Guoqiang Qiu; Xing Sun; Tao Li; Tonghai Xing; Huamei Tang; Xiao Peng; Zhihai Peng
Journal:  Ann Surg Oncol       Date:  2012-02-17       Impact factor: 5.344

6.  The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor.

Authors:  P M Brzoska; H Chen; Y Zhu; N A Levin; M H Disatnik; D Mochly-Rosen; J P Murnane; M F Christman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer.

Authors:  Yoshimasa Kosaka; Hiroshi Inoue; Takahiro Ohmachi; Takeshi Yokoe; Toshifumi Matsumoto; Koshi Mimori; Fumiaki Tanaka; Masahiko Watanabe; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2007-06-28       Impact factor: 5.344

Review 8.  Cancer stem cells in breast cancer and metastasis.

Authors:  Jessica C Lawson; Gregory L Blatch; Adrienne L Edkins
Journal:  Breast Cancer Res Treat       Date:  2009-11       Impact factor: 4.872

9.  Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.

Authors:  Lidong Wang; David G Heidt; Cheong J Lee; Huibin Yang; Craig D Logsdon; Lizhi Zhang; Eric R Fearon; Mats Ljungman; Diane M Simeone
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer.

Authors:  Hirohito Yamaguchi; Jennifer L Hsu; Mien-Chie Hung
Journal:  Front Oncol       Date:  2012-02-20       Impact factor: 6.244

View more
  22 in total

1.  Overexpression of eIF3e is correlated with colon tumor development and poor prognosis.

Authors:  Zhi Li; Shengtao Lin; Tao Jiang; Jingtao Wang; Huijun Lu; Huamei Tang; Mujian Teng; Junwei Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase.

Authors:  Huibin Yang; Phillip L Palmbos; Lidong Wang; Evelyn H Kim; Gina M Ney; Chao Liu; Jayendra Prasad; David E Misek; Xiaochun Yu; Mats Ljungman; Diane M Simeone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

3.  Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection.

Authors:  Elizabeth Lim; Matthew G Wiggans; Golnaz Shahtahmassebi; Somaiah Aroori; Matthew J Bowles; Christopher D Briggs; David A Stell
Journal:  HPB (Oxford)       Date:  2016-05-20       Impact factor: 3.647

4.  Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation.

Authors:  Jia Sun; Jing Yan; Huai-Yu Qiao; Fu-Ying Zhao; Chao Li; Jing-Yi Jiang; Bao-Qin Liu; Xiao-Na Meng; Hua-Qin Wang
Journal:  Oncogene       Date:  2019-09-09       Impact factor: 9.867

5.  Silencing of tripartite motif (TRIM) 29 inhibits proliferation and invasion and increases chemosensitivity to cisplatin in human lung squamous cancer NCI-H520 cells.

Authors:  Chunxiao Liu; Xiaoxi Huang; Shengcai Hou; Bin Hu; Hui Li
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

6.  TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling.

Authors:  Shu-Tao Tan; Sheng-Ye Liu; Bin Wu
Journal:  Cancer Res Treat       Date:  2016-03-11       Impact factor: 4.679

7.  Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway.

Authors:  Yi-Jiong Li; Guo-Ping Zhang; Feng Zhao; Rui-Qi Li; Shao-Jun Liu; Zeng-Ren Zhao; Xin Wang
Journal:  Exp Ther Med       Date:  2017-12-27       Impact factor: 2.447

Review 8.  Tumor suppressor p53 cross-talks with TRIM family proteins.

Authors:  Juan Liu; Cen Zhang; Xue Wang; Wenwei Hu; Zhaohui Feng
Journal:  Genes Dis       Date:  2020-07-16

9.  Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-κB signaling pathway.

Authors:  Xuan Su; Jianning Wang; Weichao Chen; Zhaoqu Li; Xiaoyan Fu; Ankui Yang
Journal:  Oncotarget       Date:  2016-03-01

10.  Methylation and expression of RECK, P53 and RUNX genes in patients with esophageal cancer.

Authors:  Yanrong Lu; Baerxiaguli Zabihula; Waresijiang Yibulayin; Xiang Liu
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.